Perfil de la empresa · Healthcare

ICON PLC

ICLR · EE. UU.
Bolsa
EE. UU.
País / Región
USA
Fecha de salida a bolsa
15 de mayo de 1998
Empleados
40.350
Precio actual
$168.78
En vivo · 27 de julio de 2026
Compra razonable
≤ $116
Entrada con margen de seguridad
Puntuación de crecimiento Baillie
37/100
Floja
Valor intrínseco · Rango en tres niveles Precio actual $168.78 En vivo · Dentro del rango de valor intrínseco razonable

Rango de valoración compuesto · conservador $108–$116 / razonable $145–$185 / optimista $230–$250. A $168.78, Dentro del rango de valor intrínseco razonable.

Al publicar $149.04 (12 de junio de 2026)

Capitalización12,79 mil M US$
Ingresos (TTM)8270,02 M US$
EBITDA1305,11 M US$
Margen neto2,1 %
ROE1,84 %
PER (TTM)75,35
PER previsto16,29
PEG0,55
BPA2,20 US$
Rango de 52 semanas66,57 US$ – 203,91 US$
Precio objetivo de analistas181,81 US$
Recomendación de analistas4.3 / 5

Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Historia

PróximamenteEsta sección se está completando; vuelve pronto.

Posición en el sector

PróximamenteEsta sección se está completando; vuelve pronto.

Aún no hay análisis sobre este valor en tu idioma.